Acanthamoeba keratitis: diagnosis and treatment update, Am J Ophthalmol, vol.148, pp.487-99, 2009. ,
A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis, Invest Ophthalmol Vis Sci, vol.35, pp.1059-64, 1994. ,
Voriconazole as a first-line treatment against potentially pathogenic Acanthamoeba strains from Peru, Parasitol Res, vol.113, pp.755-764, 2014. ,
Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis, Am J Ophthalmol, vol.149, pp.66-75, 2010. ,
Successful treatment of chronic stromal Acanthamoeba keratitis with oral voriconazole monotherapy, Cornea, vol.29, pp.1066-1074, 2010. ,
Polyphenol oxidase produced during encystation of Acanthamoeba castellanii, J Protozool, vol.32, pp.512-519, 1985. ,
A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents, Cornea, vol.25, pp.597-602, 2006. ,
Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis, Clin Exp Ophthalmol, vol.42, pp.151-159, 2014. ,
Drug therapy in a murine model of Acanthamoeba keratitis, Eye, vol.9, pp.142-145, 1995. ,
Multiplex real-time PCR assay for simultaneous detection of Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri, J Clin Microbiol, vol.44, pp.3589-95, 2006. ,
Human corneal stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin, Br J Ophthalmol, vol.88, pp.22-26, 2004. ,
Detection of Acanthamoeba on the ocular surface in a Spanish population using the Schirmer strip test: pathogenic potential, molecular classification and evaluation of the sensitivity to chlorhexidine and voriconazole of the isolated Acanthamoeba strains, J Med Microbiol, vol.64, pp.849-53, 2015. ,
In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri, J Eukaryot Microbiol, vol.53, pp.121-127, 2006. ,
In vitro evaluations of topical agents to treat Acanthamoeba keratitis, Ophthalmology, vol.121, pp.2059-65, 2014. ,
Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba, Graefes Arch Clin Exp Ophthalmol, vol.251, pp.2111-2118, 2013. ,
Cysticidal activity of antifungals against different genotypes of Acanthamoeba, Antimicrob Agents Chemother, vol.58, pp.5626-5634, 2014. ,
Open-label study of absorption and clearance of 1% voriconazole eye drops, Antimicrob Agents Chemother, vol.60, pp.6896-6904, 2016. ,
Topical voriconazole as a novel treatment for fungal keratitis, Antimicrob Agents Chemother, vol.50, pp.262-270, 2006. ,
Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans, Arch Ophthalmol, vol.126, pp.18-22, 2008. ,
Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses, Am J Vet Res, vol.67, pp.296-301, 2006. ,
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing, J Antimicrob Chemother, vol.69, pp.1633-1674, 2014. ,
Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans, Arch Ophthalmol, vol.122, pp.42-49, 2004. ,